A Study of Erlotinib (Tarceva) After Surgery With or Without Adjuvant Chemotherapy in Non-Small Cell Lung Carcinoma (NSCLC) Patients Who Have Epidermal Growth Factor Receptor (EGFR) Positive Tumors

NCT00373425 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

1252

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-small Cell Lung Cancer

Interventions

DRUG: Erlotinib
DRUG: Placebo

Sponsor

OSI Pharmaceuticals